Danaher Corp

Zeno argues that Danaher exemplifies a business with strong market power and sustainable growth potential, driven by its founder's mindset and disciplined capital allocation. The company operates in the healthcare sector, focusing on biotechnology, diagnostics, and life sciences, which are expected to benefit from long-term growth trends. Danaher's business model, particularly in bioprocessing, generates predictable cash flows with 88% recurring revenues, positioning it well to capitalize on the increasing demand for biologics. The manager believes that Danaher's attributes are not fully reflected in its share price, presenting an opportunity for above-normal risk-adjusted returns.

Danaher is mentioned as an example of a high-quality business that is trading below assessed fair value, which offers a compelling investment opportunity for long-term investors. The manager notes that they divested from other companies to fund larger investments in several high-quality businesses, including Danaher.

We’ve built a position in Danaher, a leading life sciences company. Danaher sells a broad mix of consumables and tooling that are mission-critical to biological R&D, diagnostic testing, and biopharma drug production. It has high market share, differentiated technology, strong management, and good growth prospects. With lower-quality earnings flushed out of the base and other parts running below trend, we expect improving, and possibly even above trend, growth over the coming years. Moreover, one of the most exciting areas of exploration for AI technology is in biopharma research. This has the potential to be a medium- to long-term accelerant for Danaher’s business. We expect EPS growth in the mid-teens.

Danaher reported results broadly consistent with expectations. However, while the company's outlook for 2026 calls for continued end market recovery, it was at a slower pace than investors hoped. Furthermore, investors appear to also have ascribed some level of 'AI risk' to Danaher on the belief that AI technology could enable customers to simulate research experiments, thus reducing the need to purchase instruments and consumables used for physical experiments in the lab. We believe that there is a low likelihood that this will ultimately occur, and even if it did happen, early-stage R&D activity represents a very small percentage of Danaher’s revenue.

Danaher, a maker of life sciences tools and diagnostics technology, lagged as biotechnology companies faced a variety of headwinds, including funding challenges and higher interest rates. However, we believe Danaher is positioned to benefit from a recovery in its markets for clinical research and semiconductor manufacturing, aided by AI discoveries.

Danaher’s earnings were largely as expected, however, the company offered a muted outlook for the coming year. Danaher has endured a difficult stretch, and we believe management is taking a more conservative guidance approach, preferring to leave room for potential positive surprises and hopefully avoid further disappointments.

Danaher is mentioned in the context of portfolio activity, where it is noted that positions in Danaher were added to on weakness. However, there is no specific argument or directional stance provided regarding its future performance or valuation.

Danaher saw weak share price performance in 2025, in part because investors were not sufficiently excited about its guidance. But we believe it is an excellent business. Our portfolio has almost never been so cheaply valued relative to the benchmark. We therefore own a collection of businesses that, in aggregate, grow faster and earn higher returns than the market but are priced more conservatively than they have been in the past. This, in our view, is a promising set-up for future success.

We believe Danaher Corporation exemplifies the power of long-term compounding through its unique management philosophy, which has compounded investors' capital at over 21% per year for 40 years. The 'Danaher Business System' has created a culture that fosters continuous improvement and employee empowerment, aligning with our investment criteria of humility, integrity, and long-term focus. This cultural strength positions Danaher to continue delivering exceptional returns, and we are optimistic about its future prospects as we add to our position.

Danaher experienced mixed organic revenue growth in the first quarter, reporting flat overall growth. The Biotechnology segment (30% of annual revenues) was a bright spot, reporting a strong 7% organic revenue increase. This marks a significant recovery from the double-digit declines seen a year ago and represents the second consecutive quarter of high-single-digit growth for the segment. The company anticipates this trend to continue, guiding for high-single-digit growth in Biotechnology for both 2025 and the long term. Conversely, the Life Sciences and Diagnostics segments continued to report negative growth. Life Sciences was particularly impacted by weaker instrument sales and soft consumables within its genomics business. Additionally, demand from academic and government sectors softened throughout the quarter. The Diagnostics business faced challenges due to volume-based procurement and reimbursement changes implemented in China in late 2024. The remainder of the Diagnostics portfolio, however, delivered modest growth. Overall, Danaher expects low-single-digit revenue growth for the full year, with the ability to largely offset the impact of tariffs.